GlassScriptPhysician profile
Zackary Knott
NPI 1245691161
$963.97
in general payments reported to CMS, 2019-2025
11 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.98 · 2021: $109 · 2022: $274 · 2023: $124 · 2024: $102 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.95 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $140.07 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $113.66 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.29 | 2020-2023 | Eliquis |
| Mallinckrodt Hospital Products INC. | $86.46 | 2024-2025 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $55.71 | 2023-2025 | Ultomiris |
| Smith+Nephew, INC. | $49.43 | 2023-2025 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.18 | 2025 | Xifaxan |
| Pfizer INC. | $33.74 | 2022 | |
| Merck Sharp & Dohme LLC | $17.52 | 2022 | |
| Gilead Sciences, INC. | $14.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zackary Knott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.